Developer docs
API playgroundTry for free, no card

Search company profiles

Converge Bio

Full company profile

uuid0000mjn

Namestring
Converge Bio
Legal namestring
Converge Bio, Inc.
Company typeenum
Private
Founded yearint
2024
Descriptiontext

Converge Bio is a privately held, venture-backed AI drug discovery company founded in 2024 and headquartered in Boston and Tel Aviv, with a Delaware-incorporated US entity (Converge Bio, Inc.) and an Israeli operating entity. The company builds a generative AI platform — branded as the Converge Computational Lab — composed of proprietary bio-LLM foundation models trained on the core biological languages of DNA, RNA, and protein sequences, and delivered as fully managed, dedicated private instances that can also be deployed on customer cloud infrastructure. Three flagship product modules share the underlying model library: ConvergeAB™ for antibody design and engineering (de novo design, affinity maturation, humanization, developability, and IP expansion across IgG, scFv, VHH, and bispecific formats); ConvergeGEO™ for gene expression and protein yield optimization across CHO, HEK293, E. coli, Pichia, S. cerevisiae, and A. oryzae; and ConvergeCELL™ for virtual cell, target, and biomarker discovery from single-cell and bulk transcriptomic data. A separate Converge-SC model handles single-cell RNA interpretation, and a free Patent Extractor tool supports antibody sequence extraction from patent documents.

The business model is enterprise SaaS delivered through a high-touch, expert-led sales motion targeting pharmaceutical and biotech customers. Pricing is not publicly disclosed; engagements are quote-based on multi-year contracts with customer-owned IP and dedicated isolated deployments. Converge reports 40+ completed programs for 12+ customers across the US, Canada, Europe, and Israel, with named logos including Purple Biotech, Compugen, and PreFer Industries. Revenue is supplemented by non-dilutive grant funding, most notably a $2.5M, 37-month Gates Foundation grant (June 2026) to extend the platform into crop genomics. As of the January 2026 Series A, the company had grown to roughly 34-40 employees, and has raised a total of $30M in equity across a $5.5M seed (TLV Partners, November 2024) and a $25M oversubscribed Series A (Bessemer Venture Partners lead, January 2026).

Short descriptiontext

Converge Bio builds generative AI foundation models (bio-LLMs) for antibody design, protein expression optimization, and target/biomarker discovery, selling dedicated private instances on a multi-year enterprise basis to pharmaceutical and biotech customers across the US, Canada, Europe, and Israel.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersWilmington, United States
HQ citystring
Wilmington
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI drug discovery, generative biology, antibody design platform, protein expression optimization, biomarker discovery
Industry3 codes
PRIMARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGANAI
Bioinformatics, Multi-Omics Data Analysis & Interpretation Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
AI Drug Discovery / Computational Biology Platform
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Enterprise SaaS / AI platform subscriptions and programs
TypeSubscription Recurring
Description

Revenue generated from selling access to the Converge computational lab (ConvergeAB, ConvergeGEO, ConvergeCELL) deployed as dedicated private instances for pharma and biotech customers. Customers engage on a program basis for target discovery, antibody design, and protein manufacturing optimization. The company has completed over 40 programs with more than a dozen pharmaceutical and biotech customers.

techcrunch.com
2Grant funding (non-dilutive)
TypeManaged Services
Description

Non-dilutive grant funding from foundations and government-aligned programs; a $2.5M, 37-month grant from the Gates Foundation to extend the platform into crop genomics represents the first material example. Grant funding supplements platform and program revenue.

prnewswire.com
3Professional / expert services bundled with platform access
TypeProfessional Services
Description

Converge's GTM bundles its scientists and AI experts in a closed-loop partnership with customers, supporting design and discovery from setup through scaling. Expert support is part of the platform offering.

converge-bio.com
Marketing channels11 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations
Pricing details2 tiers
1Quote-based enterprise pricing; not publicly disclosed
ModelOtherBilling cadenceMulti-year contract
Notes

Pricing is not publicly listed; customers must request access or book a meeting to discuss. Each deployment is a dedicated, isolated instance with full IP ownership retained by the customer.

converge-bio.com
2Free Patent Extractor (limited)
ModelFreemiumBilling cadencePay-as-you-go
Notes

Free online tool with a cap on the number of patents each user email can submit; higher-volume access available on request.

converge-bio.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 4 records shown
1ConvergeAB™
Description

Generative AI platform for antibody design and engineering, supporting de novo design, affinity maturation, humanization, and developability optimization across IgG, VHH, scFv, and bispecific formats.

converge-bio.com
+3 more records
Core offering1 text field

Converge Bio sells a Generative AI platform called the Converge Computational Lab, built on bio-LLMs trained on DNA, RNA, and protein sequences, and delivered to pharma and biotech customers as dedicated, private cloud instances. The platform comprises three flagship modules — ConvergeAB (antibody design), ConvergeGEO (gene expression / protein yield optimization), and ConvergeCELL (virtual cell and target/biomarker discovery) — supported by a free Converge Patent Extractor tool and the Converge-SC single-cell LLM. Customers engage on a multi-year program basis combining platform access with co-development by Converge's scientists and AI experts.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 8 values shown
  • 4.5x protein yield increase for PreFer Industries using the same production system
+7 more records
Product overview1 text field

Converge Bio offers a unified Generative AI platform for the life sciences, branded as the Converge Computational Lab, with three integrated product modules plus a free add-on tool. The platform is built on foundation models trained on the core biological languages of DNA, RNA, and protein sequences and is delivered as a managed, fully hosted service with private-by-design data isolation. The three core modules are: ConvergeAB™, an antibody design and engineering platform supporting de novo design, affinity maturation, humanization, and IP expansion; ConvergeGEO™, a generative protein yield optimization solution for CHO, HEK293, E. coli, Pichia, S. cerevisiae, and A. oryzae expression systems; and ConvergeCELL™, a virtual cell and precision medicine platform for biomarker and target discovery built on a patient-level single-cell foundation model. A separate large language model, Converge-SC, addresses single-cell RNA interpretation, and the free Converge Patent Extractor tool extracts structured antibody intelligence from patent filings. Together the products span target discovery, antibody design, protein manufacturing optimization, and biomarker discovery across the drug discovery life cycle.

Product and service5 records
1ConvergeAB™
CategoryAI antibody design platform
Description

Generative AI platform for antibody design and engineering, supporting de novo design, affinity maturation, humanization, and developability optimization across IgG, scFv, VHH, and bispecific formats. Trained on over 1 trillion natural protein tokens, 7M antibody sequences, 3M antibody-antigen pairs, and 10,000 developability measurements; generates ~100,000 target-aware candidates per campaign and filters them through orthogonal predictors for binding, stability, solubility, and structural fit. Sold to pharma and biotech R&D teams as part of the Converge Computational Lab.

2ConvergeGEO™
CategoryAI protein expression optimization platform
Description

Generative AI yield optimization solution that designs host-specific DNA sequences (codons, UTRs, promoters, terminators) to maximize protein output across CHO, HEK293, E. coli, Pichia (K. phaffii), S. cerevisiae, and A. oryzae expression systems. Trained on 1+ trillion gene tokens and 100M+ expression profiles; benchmarked zero-shot to outperform GenScript, Twist, IDT, and ThermoFisher (p = 0.012) with customer-validated 4.5x–7x yield improvements. Sold to pharma and biotech manufacturing and process development teams.

3ConvergeCELL™
CategoryAI target and biomarker discovery platform
Description

Patient-level single-cell and bulk transcriptomics foundation model for target and biomarker discovery, trained on 23M+ cells from 5,000 patient samples, 550 studies, and 40 clinical indications. Uses supervised contrastive learning to learn patient embeddings from single-cell data and knowledge distillation to extend the representation to bulk RNA-seq; includes a hypothesis-generation agent that connects an LLM to PubMed, Open Targets, and ClinicalTrials.gov to produce structured mechanism-of-action hypothesis cards. Validated zero-shot on SLE (AUROC 0.87), multiple myeloma (AUROC 0.72), and sepsis. Sold to pharma and biotech discovery and translational teams.

4Converge-SC
CategorySingle-cell RNA sequencing language model
Description

Large language model that interprets single-cell RNA sequencing data, capable of processing over 20,000 genes per cell and trained on more than 36 million cells, supporting precision medicine and drug discovery through patient-level analysis. Deployed on Nebius infrastructure.

5Converge Patent Extractor
CategoryAntibody patent intelligence tool
Description

Free online tool that extracts antibody-related information (sequences, CDRs, variants, targets, binding/affinity data) from US, EP, WO, and AU patent documents. Reads ST.26 XML, ST.25 listings, pre-ST.25 prose, FASTA dumps, and scanned PDFs via vision OCR; benchmarked at 98% agreement with PLAbDab on 500+ patents and 2.8x more antibodies recovered. Offered free with a per-email submission cap to computational biologists and antibody discovery scientists.

Scale indicator16 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierFlagship / First Major Grant Partner And Agricultural Expansion AnchorTypeStrategic or Co-development PartnerAnnounced on2026-06-01
Description

Awarded Converge Bio a $2.5M, 37-month grant in June 2026 to extend its generative AI platform from pharmaceutical research into agricultural biotechnology, specifically crop genomics. The initiative develops a multimodal foundation model to identify genetic variants linked to yield and climate resilience, supporting the Gates Foundation's goal of helping smallholder farmers in sub-Saharan Africa and South Asia adapt to climate volatility.

Strategic tierCore / Strategic Oncology CollaborationTypeStrategic or Co-development PartnerAnnounced on2026-05-01
Description

Expanded its collaboration with Converge Bio to apply generative AI to antibody design and established a Scientific Advisory Board to support the CAPTN-3 platform development toward first-in-human studies in 2027, as part of Purple Biotech's Q1 2026 results announcement.

Strategic tierCore / Strategic Oncology CollaborationTypeStrategic or Co-development PartnerAnnounced on2026-03-25
Description

Collaboration announced March 25, 2026 to leverage Converge Bio's generative AI to accelerate development of Purple Biotech's CAPTN-3 tri-specific antibody platform targeting solid tumors. The AI-driven approach is designed to reduce discovery timelines, improve candidate quality, and expand the CAPTN-3 platform to additional high-value oncology targets and resistance mechanisms, including T cell engagers and NK cell engagers.

Strategic tierCore / Ai Compute Infrastructure PartnerTypeTechnology or IntegrationAnnounced on2025-05-01
Description

Converge Bio is using Nebius AI cloud infrastructure to support single-cell research and precision-medicine workloads, including the Converge-SC model. Highlighted as a partner case study in Nebius's monthly digest in May 2025.

Strategic tierMinor / Early CollaborationTypeStrategic or Co-development PartnerAnnounced on2024-09-01
Description

Announced an 'Exciting Collaboration' with Converge Bio in September 2024, referenced on Converge Bio's news page as an early antibody design collaboration.

Strategic tierFlagship / Accelerator Partner With Co-Marketing And Cloud CreditsTypeGTM or Marketing PartnerAnnounced on2024-09-01
Description

Converge Bio was selected to participate in the 2024 AWS Generative AI Accelerator program, an $230M AWS initiative promoting generative AI applications. Converge Bio received mentorship, funding, and go-to-market support, and was part of an 80-startup cohort from 129 countries receiving up to $1M in AWS credits.

Strategic tierCore / Open-Source Distribution And Research Community ChannelTypeOEM/ Whitelabel/ Licensing Partner
Description

ConvergeCELL's patient representation engine is published open source on Hugging Face (huggingface.co/ConvergeBio) to empower the research community and build Converge Bio's developer/credential footprint.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

EvolutionaryScale is a research-driven AI company building large biological foundation models (ESM family) for protein design and therapeutic discovery. It overlaps with Converge's protein-language-model approach but is focused on general-purpose foundation models rather than full-stack pharma delivery.

TypeEmerging player
Description

Profluent Bio builds AI foundation models for protein design, including antibodies. It is an emerging competitor in AI-driven protein engineering with overlapping capabilities to ConvergeAB but operates at a more research-focused stage.

TypeDirect peer
Description

Generate Biomedicines is a generative biology company building foundation models to design novel protein therapeutics. It directly competes with ConvergeAB in AI-driven antibody and protein design and shares the same foundation-model architecture philosophy.

TypeBroad incumbent
Description

Absci is a generative AI drug creation company combining generative AI with a proprietary wet-lab platform for antibody discovery and design. As a public company with established pharma partnerships, it is an incumbent competitor to ConvergeAB.

TypeBroad incumbent
Description

Recursion is an established clinical-stage TechBio combining high-throughput experimental biology with AI/ML for drug discovery. As a public incumbent with multiple partnerships and programs, it represents a broader competitor in the AI-driven pharma discovery space.

6Isomorphic Labs
TypeBroad incumbent
Description

Isomorphic Labs is Alphabet's commercial AI drug discovery subsidiary spun out of DeepMind's AlphaFold work. It operates broadly across the same AI-driven therapeutic discovery space as Converge and represents a well-capitalized incumbent with deep-pocketed Big Tech backing.

TypeBroad incumbent
Description

AbCellera is a clinical-stage biotech that combines a proprietary antibody discovery platform with internal development programs. It is an established incumbent in AI-augmented antibody discovery and overlaps with ConvergeAB's antibody design capabilities.

TypeDirect peer
Description

BigHat Biosciences combines generative AI with wet-lab experimentation to design antibody therapeutics. It competes directly with ConvergeAB's de novo design, affinity maturation, and developability optimization capabilities.

TypeDirect peer
Description

Cradle is a generative AI protein design platform focused on engineering biologics including antibodies and enzymes. Converge explicitly benchmarks against Cradle (4.4x stronger binding than a Cradle-derived competitor), and the two compete head-to-head in AI-driven antibody and protein design for pharma.

TypeDirect peer
Description

Insitro is a machine learning-driven drug discovery company combining high-throughput biology with ML models to discover therapeutics. It overlaps directly with ConvergeCELL's target/biomarker discovery mission and competes for the same large-pharma partnerships.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability11 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Converge Bio

AI Drug Discovery / Computational Biology Platformconverge-bio.com

Converge Bio builds generative AI foundation models (bio-LLMs) for antibody design, protein expression optimization, and target/biomarker discovery, selling dedicated private instances on a multi-year enterprise basis to pharmaceutical and biotech customers across the US, Canada, Europe, and Israel.

What Converge Bio does

Converge Bio is a privately held, venture-backed AI drug discovery company founded in 2024 and headquartered in Boston and Tel Aviv, with a Delaware-incorporated US entity (Converge Bio, Inc.) and an Israeli operating entity. The company builds a generative AI platform — branded as the Converge Computational Lab — composed of proprietary bio-LLM foundation models trained on the core biological languages of DNA, RNA, and protein sequences, and delivered as fully managed, dedicated private instances that can also be deployed on customer cloud infrastructure. Three flagship product modules share the underlying model library: ConvergeAB™ for antibody design and engineering (de novo design, affinity maturation, humanization, developability, and IP expansion across IgG, scFv, VHH, and bispecific formats); ConvergeGEO™ for gene expression and protein yield optimization across CHO, HEK293, E. coli, Pichia, S. cerevisiae, and A. oryzae; and ConvergeCELL™ for virtual cell, target, and biomarker discovery from single-cell and bulk transcriptomic data. A separate Converge-SC model handles single-cell RNA interpretation, and a free Patent Extractor tool supports antibody sequence extraction from patent documents.

The business model is enterprise SaaS delivered through a high-touch, expert-led sales motion targeting pharmaceutical and biotech customers. Pricing is not publicly disclosed; engagements are quote-based on multi-year contracts with customer-owned IP and dedicated isolated deployments. Converge reports 40+ completed programs for 12+ customers across the US, Canada, Europe, and Israel, with named logos including Purple Biotech, Compugen, and PreFer Industries. Revenue is supplemented by non-dilutive grant funding, most notably a $2.5M, 37-month Gates Foundation grant (June 2026) to extend the platform into crop genomics. As of the January 2026 Series A, the company had grown to roughly 34-40 employees, and has raised a total of $30M in equity across a $5.5M seed (TLV Partners, November 2024) and a $25M oversubscribed Series A (Bessemer Venture Partners lead, January 2026).

Converge Bio firmographics

Firmographics
Name
Converge Bio
Legal name
Converge Bio, Inc.
Website
https://converge-bio.com
Company type
Private
Founded year
2024
Operating status
Operating
Headcount range
51–100 employees
Short description
Converge Bio builds generative AI foundation models (bio-LLMs) for antibody design, protein expression optimization, and target/biomarker discovery, selling dedicated private instances on a multi-year enterprise basis to pharmaceutical and biotech customers across the US, Canada, Europe, and Israel.
Ownership category
akta.pro rank

Converge Bio industry classification

Industry
Product category
AI Drug Discovery / Computational Biology Platform
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGANAI
Bioinformatics, Multi-Omics Data Analysis & Interpretation Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

Keywords

  • AI drug discovery
  • Generative biology
  • Antibody design platform
  • Protein expression optimization
  • Biomarker discovery

Where Converge Bio is headquartered

Location

Headquarters

HQ city
Wilmington
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Converge Bio business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations

Revenue model

  1. Enterprise SaaS / AI platform subscriptions and programs: Revenue generated from selling access to the Converge computational lab (ConvergeAB, ConvergeGEO, ConvergeCELL) deployed as dedicated private instances for pharma and biotech customers. Customers engage on a program basis for target discovery, antibody design, and protein manufacturing optimization. The company has completed over 40 programs with more than a dozen pharmaceutical and biotech customers.
  2. Grant funding (non-dilutive): Non-dilutive grant funding from foundations and government-aligned programs; a $2.5M, 37-month grant from the Gates Foundation to extend the platform into crop genomics represents the first material example. Grant funding supplements platform and program revenue.
  3. Professional / expert services bundled with platform access: Converge's GTM bundles its scientists and AI experts in a closed-loop partnership with customers, supporting design and discovery from setup through scaling. Expert support is part of the platform offering.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractQuote-based enterprise pricing; not publicly disclosed
FreemiumPay-as-you-goFree Patent Extractor (limited)

Go-to-market motion3 records

Distribution channels4 records

Marketing channels11 records

Converge Bio product offering

Product offering

Core offering

Converge Bio sells a Generative AI platform called the Converge Computational Lab, built on bio-LLMs trained on DNA, RNA, and protein sequences, and delivered to pharma and biotech customers as dedicated, private cloud instances. The platform comprises three flagship modules — ConvergeAB (antibody design), ConvergeGEO (gene expression / protein yield optimization), and ConvergeCELL (virtual cell and target/biomarker discovery) — supported by a free Converge Patent Extractor tool and the Converge-SC single-cell LLM. Customers engage on a multi-year program basis combining platform access with co-development by Converge's scientists and AI experts.

Product overview

Converge Bio offers a unified Generative AI platform for the life sciences, branded as the Converge Computational Lab, with three integrated product modules plus a free add-on tool. The platform is built on foundation models trained on the core biological languages of DNA, RNA, and protein sequences and is delivered as a managed, fully hosted service with private-by-design data isolation. The three core modules are: ConvergeAB™, an antibody design and engineering platform supporting de novo design, affinity maturation, humanization, and IP expansion; ConvergeGEO™, a generative protein yield optimization solution for CHO, HEK293, E. coli, Pichia, S. cerevisiae, and A. oryzae expression systems; and ConvergeCELL™, a virtual cell and precision medicine platform for biomarker and target discovery built on a patient-level single-cell foundation model. A separate large language model, Converge-SC, addresses single-cell RNA interpretation, and the free Converge Patent Extractor tool extracts structured antibody intelligence from patent filings. Together the products span target discovery, antibody design, protein manufacturing optimization, and biomarker discovery across the drug discovery life cycle.

Differentiator

Problem solved

Functional benefit

Brands

  • ConvergeAB™: Generative AI platform for antibody design and engineering, supporting de novo design, affinity maturation, humanization, and developability optimization across IgG, VHH, scFv, and bispecific formats.
  • ConvergeGEO™
  • ConvergeCELL™
  • Converge Patent Extractor

Products and services

  • ConvergeAB™ Generative AI platform for antibody design and engineering, supporting de novo design, affinity maturation, humanization, and developability optimization across IgG, scFv, VHH, and bispecific formats. Trained on over 1 trillion natural protein tokens, 7M antibody sequences, 3M antibody-antigen pairs, and 10,000 developability measurements; generates ~100,000 target-aware candidates per campaign and filters them through orthogonal predictors for binding, stability, solubility, and structural fit. Sold to pharma and biotech R&D teams as part of the Converge Computational Lab.
  • ConvergeGEO™ Generative AI yield optimization solution that designs host-specific DNA sequences (codons, UTRs, promoters, terminators) to maximize protein output across CHO, HEK293, E. coli, Pichia (K. phaffii), S. cerevisiae, and A. oryzae expression systems. Trained on 1+ trillion gene tokens and 100M+ expression profiles; benchmarked zero-shot to outperform GenScript, Twist, IDT, and ThermoFisher (p = 0.012) with customer-validated 4.5x–7x yield improvements. Sold to pharma and biotech manufacturing and process development teams.
  • ConvergeCELL™ Patient-level single-cell and bulk transcriptomics foundation model for target and biomarker discovery, trained on 23M+ cells from 5,000 patient samples, 550 studies, and 40 clinical indications. Uses supervised contrastive learning to learn patient embeddings from single-cell data and knowledge distillation to extend the representation to bulk RNA-seq; includes a hypothesis-generation agent that connects an LLM to PubMed, Open Targets, and ClinicalTrials.gov to produce structured mechanism-of-action hypothesis cards. Validated zero-shot on SLE (AUROC 0.87), multiple myeloma (AUROC 0.72), and sepsis. Sold to pharma and biotech discovery and translational teams.
  • Converge-SC Large language model that interprets single-cell RNA sequencing data, capable of processing over 20,000 genes per cell and trained on more than 36 million cells, supporting precision medicine and drug discovery through patient-level analysis. Deployed on Nebius infrastructure.
  • Converge Patent Extractor Free online tool that extracts antibody-related information (sequences, CDRs, variants, targets, binding/affinity data) from US, EP, WO, and AU patent documents. Reads ST.26 XML, ST.25 listings, pre-ST.25 prose, FASTA dumps, and scanned PDFs via vision OCR; benchmarked at 98% agreement with PLAbDab on 500+ patents and 2.8x more antibodies recovered. Offered free with a per-email submission cap to computational biologists and antibody discovery scientists.

Quantifiable outcome

  • 4.5x protein yield increase for PreFer Industries using the same production system
  • +7 more outcomes

Companies that use Converge Bio

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles4 records

Converge Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability11 records

Feature7 records

Converge Bio partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered flagship / first major grant partner and agricultural expansion anchor, core / strategic oncology collaboration, core / ai compute infrastructure partner, minor / early collaboration, flagship / accelerator partner with co-marketing and cloud credits and core / open-source distribution and research community channel.

  • Gates Foundationflagship / first major grant partner and agricultural expansion anchorStrategic or Co-development Partner · 1 June 2026Awarded Converge Bio a $2.5M, 37-month grant in June 2026 to extend its generative AI platform from pharmaceutical research into agricultural biotechnology, specifically crop genomics. The initiative develops a multimodal foundation model to identify genetic variants linked to yield and climate resilience, supporting the Gates Foundation's goal of helping smallholder farmers in sub-Saharan Africa and South Asia adapt to climate volatility.
  • Purple Biotech (expanded collaboration)core / strategic oncology collaborationStrategic or Co-development Partner · 1 May 2026Expanded its collaboration with Converge Bio to apply generative AI to antibody design and established a Scientific Advisory Board to support the CAPTN-3 platform development toward first-in-human studies in 2027, as part of Purple Biotech's Q1 2026 results announcement.
  • Purple Biotechcore / strategic oncology collaborationStrategic or Co-development Partner · 25 March 2026Collaboration announced March 25, 2026 to leverage Converge Bio's generative AI to accelerate development of Purple Biotech's CAPTN-3 tri-specific antibody platform targeting solid tumors. The AI-driven approach is designed to reduce discovery timelines, improve candidate quality, and expand the CAPTN-3 platform to additional high-value oncology targets and resistance mechanisms, including T cell engagers and NK cell engagers.
  • Nebiuscore / ai compute infrastructure partnerTechnology or Integration · 1 May 2025Converge Bio is using Nebius AI cloud infrastructure to support single-cell research and precision-medicine workloads, including the Converge-SC model. Highlighted as a partner case study in Nebius's monthly digest in May 2025.
  • Compugenminor / early collaborationStrategic or Co-development Partner · 1 September 2024Announced an 'Exciting Collaboration' with Converge Bio in September 2024, referenced on Converge Bio's news page as an early antibody design collaboration.
  • Amazon Web Services (AWS)flagship / accelerator partner with co-marketing and cloud creditsGTM or Marketing Partner · 1 September 2024Converge Bio was selected to participate in the 2024 AWS Generative AI Accelerator program, an $230M AWS initiative promoting generative AI applications. Converge Bio received mentorship, funding, and go-to-market support, and was part of an 80-startup cohort from 129 countries receiving up to $1M in AWS credits.
  • Hugging Facecore / open-source distribution and research community channelOEM/ Whitelabel/ Licensing PartnerConvergeCELL's patient representation engine is published open source on Hugging Face (huggingface.co/ConvergeBio) to empower the research community and build Converge Bio's developer/credential footprint.

Scale indicators16 records

Recent moves7 records

Expansion highlights6 records

Converge Bio competitors and assessment

Company assessment

Emerging players

  • EvolutionaryScale: EvolutionaryScale is a research-driven AI company building large biological foundation models (ESM family) for protein design and therapeutic discovery. It overlaps with Converge's protein-language-model approach but is focused on general-purpose foundation models rather than full-stack pharma delivery.
  • Profluent Bio: Profluent Bio builds AI foundation models for protein design, including antibodies. It is an emerging competitor in AI-driven protein engineering with overlapping capabilities to ConvergeAB but operates at a more research-focused stage.

Direct peers

  • Generate Biomedicines: Generate Biomedicines is a generative biology company building foundation models to design novel protein therapeutics. It directly competes with ConvergeAB in AI-driven antibody and protein design and shares the same foundation-model architecture philosophy.
  • BigHat Biosciences: BigHat Biosciences combines generative AI with wet-lab experimentation to design antibody therapeutics. It competes directly with ConvergeAB's de novo design, affinity maturation, and developability optimization capabilities.
  • Cradle Bio: Cradle is a generative AI protein design platform focused on engineering biologics including antibodies and enzymes. Converge explicitly benchmarks against Cradle (4.4x stronger binding than a Cradle-derived competitor), and the two compete head-to-head in AI-driven antibody and protein design for pharma.
  • Insitro: Insitro is a machine learning-driven drug discovery company combining high-throughput biology with ML models to discover therapeutics. It overlaps directly with ConvergeCELL's target/biomarker discovery mission and competes for the same large-pharma partnerships.

Broad incumbents

  • Absci: Absci is a generative AI drug creation company combining generative AI with a proprietary wet-lab platform for antibody discovery and design. As a public company with established pharma partnerships, it is an incumbent competitor to ConvergeAB.
  • Recursion Pharmaceuticals: Recursion is an established clinical-stage TechBio combining high-throughput experimental biology with AI/ML for drug discovery. As a public incumbent with multiple partnerships and programs, it represents a broader competitor in the AI-driven pharma discovery space.
  • Isomorphic Labs: Isomorphic Labs is Alphabet's commercial AI drug discovery subsidiary spun out of DeepMind's AlphaFold work. It operates broadly across the same AI-driven therapeutic discovery space as Converge and represents a well-capitalized incumbent with deep-pocketed Big Tech backing.
  • AbCellera: AbCellera is a clinical-stage biotech that combines a proprietary antibody discovery platform with internal development programs. It is an established incumbent in AI-augmented antibody discovery and overlaps with ConvergeAB's antibody design capabilities.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Converge Bio social profiles

Digital presence

Converge Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Converge Bio leadership team

Management profile

Number of profiles

Profiles6 records

Converge Bio funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Converge Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Converge Bio

What does Converge Bio do?

Converge Bio sells a Generative AI platform called the Converge Computational Lab, built on bio-LLMs trained on DNA, RNA, and protein sequences, and delivered to pharma and biotech customers as dedicated, private cloud instances. The platform comprises three flagship modules — ConvergeAB (antibody design), ConvergeGEO (gene expression / protein yield optimization), and ConvergeCELL (virtual cell and target/biomarker discovery) — supported by a free Converge Patent Extractor tool and the Converge-SC single-cell LLM. Customers engage on a multi-year program basis combining platform access with co-development by Converge's scientists and AI experts.

Is Converge Bio a public or private company?

Converge Bio is a private company. It is classified as venture growth investor backed and is currently operating.

When was Converge Bio founded?

Converge Bio was founded in 2024. It employs 51 to 100 people.

Where is Converge Bio based?

Converge Bio is headquartered in Wilmington, United States, in the North America region.

How does Converge Bio make money?

Three revenue lines are on record. Enterprise SaaS / AI platform subscriptions and programs are the primary driver. The others are grant funding (non-dilutive) and professional / expert services bundled with platform access.

Who are Converge Bio's main competitors?

Emerging players on record are EvolutionaryScale and Profluent Bio. Direct peers are Generate Biomedicines, BigHat Biosciences, Cradle Bio and Insitro. Broad incumbents are Absci, Recursion Pharmaceuticals, Isomorphic Labs and AbCellera.

Does Converge Bio have an API?

No public API is recorded for Converge Bio.

What industry is Converge Bio in?

Converge Bio's product category is AI Drug Discovery / Computational Biology Platform. Its primary akta.pro industry code is HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening), with a secondary code of HLAGANAI, Bioinformatics, Multi-Omics Data Analysis & Interpretation Services. Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
ForbesHow Biotech And Pharma Adopt AI And The Supply Chain OpportunitiesNVIDIA's report finds 74% of pharma and biotech organizations use AI, with 47% reporting ROI. Pathos, GenBio, Telesis Bio, and Converge Bio are deploying AI agents, cell models, DNA synthesis, and antibody design. Life science M&A is rising, with deal values up 123%.In VivoBiotech Investors Are Waiting For The Wrong Milestone In AI Drug DiscoveryConverge Bio's CEO Dov Gertz argues that biotech investors are focused on the wrong milestone when evaluating AI drug discovery companies, fixating on FDA approvals rather than the value that compounds at the platform layer years earlier. The article suggests that unlike other AI industries where revenue appears rapidly, biotechnology operates on a different timeline, and the metrics that actually reveal AI drug discovery value can be measured now. This represents an opinion piece on investment strategy rather than a report of a specific event.Aijourn7 Best AI Drug Discovery Platforms for 2026This article ranks seven AI drug discovery platforms for 2026, highlighting Converge Bio as the top choice for biotech and pharma teams seeking generative AI systems built around practical life sciences workflows. The platforms collectively represent a shift from basic prediction tools toward comprehensive systems supporting antibody design, small molecule generation, protein engineering, and translational science decisions. The most useful platforms now focus on connecting computational outputs to specific scientific bottlenecks rather than offering generic AI models.iGrow NewsConverge Bio Receives $2.5M Gates Foundation Grant to Extend AI Platform to Crop GenomicsConverge Bio has been awarded a $2.5 million, 37-month grant from the Gates Foundation to extend its generative AI drug modeling platform into crop genomics, marking the company's first major expansion from human health into agricultural science. The funding will support development of a multimodal foundation model that analyzes crop genomes as interconnected systems to identify genetic variants linked to yield and climate resilience, potentially shortening the traditional 12-15 year crop breeding timeline. The initiative aims to help researchers and growers identify high-resilience genetic patterns earlier in the breeding process to support long-term global food security.citybizConverge Bio Lands $2.5M Gates Foundation Grant to Bring AI Drug Discovery Technology to Climate-Resilient CropsConverge Bio has secured a $2.5 million multi-year grant from the Gates Foundation to apply its generative AI platform, originally developed for pharmaceutical research, to crop genomics and climate-resilient agriculture. The funding will support a 37-month initiative to build a multimodal foundation model that analyzes genomic data to identify genetic variants associated with crop yield and climate resilience, potentially reducing the 12-15 year timeline traditionally required to bring new crop varieties to market. The project positions Converge Bio to demonstrate that AI-driven biological modeling can extend beyond healthcare into agricultural science, addressing food security challenges as climate pressures intensify on global food systems.PR NewswireConverge Bio Secures $2.5M Grant to expand its fast-track AI gene discovery capabilities from pharma to growing climate-resilient cropsConverge Bio has received a $2.5 million multi-year grant from the Gates Foundation to adapt its AI drug modeling platform for crop genomics, marking the company's expansion from human health into agricultural science. The initiative aims to develop a multimodal foundation model that analyzes crop genomes to identify genetic variants linked to yield and climate resilience, with the goal of shortening the traditional 12-15 year crop breeding cycle. The collaboration supports the Gates Foundation's goal of helping smallholder farmers in sub-Saharan Africa and South Asia adapt to increasing climate volatility.FinSMEsConverge Bio Receives $2.5M Grant From Bill & Melinda Gates FoundationConverge Bio, a Boston-based AI company developing generative foundation models for life sciences, has received a $2.5 million non-dilutive grant from the Bill & Melinda Gates Foundation. The company intends to use the funding to expand its drug modeling platform into crop genomics, build multimodal long-context DNA foundation models, and accelerate breeding timelines for climate-resilient plants. The grant marks an expansion of the company's AI capabilities from therapeutic applications into agricultural biotechnology.Stock TitanPurple Biotech Q1 2026 results, $6.4M cash runwayPurple Biotech Ltd. reported Q1 2026 financial results with an adjusted operating loss of $2.1 million, up from $1.3 million in Q1 2025, driven by increased R&D spending on the CAPTN-3 platform. The company announced new patient-derived tumor data for its lead tri-specific antibody IM1240 showing anti-tumor activity across treatment-resistant samples, along with the establishment of a CAPTN-3 Scientific Advisory Board and an expanded AI collaboration with Converge Bio. Purple Biotech ended Q1 2026 with $6.4 million in cash, which management expects will provide runway into 2027.WowtaleOne new drug costs 10 years and 1 trillion won, AI is breaking this formula: AI biotech landscape 2026AI drug development is organized into seven layers, with venture capital exceeding $11 billion in 2025. No AI-designed drug has completed Phase 3 trials and received approval yet, but Insilico Medicine's IPF treatment passed Phase 2a. 2026-2027 will test the most advanced pipelines.